'Phase 0' Trials Aim to Speed Cancer Drug Development -- Even after years of painstaking research and testing, only a small percentage of cancer agents make it from the laboratory to the patient. Phase 0 studies expose a small number of people to low doses of a drug over a limited period of time -- seven days or less. As the name implies, a phase 0 trial precedes "phase I" testing, traditionally the first step in the process of human drug testing. So scientists have come up with a way to weed out the duds earlier in the process and speed good medications to the marketplace.

The new model, a so-called "phase 0" clinical trial, promises to streamline the costly and time-consuming drug development process, helping to deliver good drugs to people who need them more quickly. Doroshow, director of the division of cancer treatment and diagnosis at the National Cancer Institute in Bethesda, Md. "We want to find out if they're ineffective in the smallest number of patients and get definitive information as mathe in the development process as possible," said Dr.

In a phase I study, the goal is to determine the best way to administer a drug and the maximum dose tolerated with the fewest side effects.